NCT04116827

Brief Summary

The aim of this study is to observe the sleep and activity patterns of pre-menopausal breast cancer patients taking tamoxifen using a wrist-worn internet of things device and questionnaires.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Aug 2018

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 10, 2018

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

October 3, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 7, 2019

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
Last Updated

October 7, 2019

Status Verified

October 1, 2019

Enrollment Period

2.4 years

First QC Date

October 3, 2019

Last Update Submit

October 3, 2019

Conditions

Keywords

sleep disorderbreast cancerpre-menopausaltamoxifenhormone therapy

Outcome Measures

Primary Outcomes (2)

  • total sleep time

    mean total sleep time per day, recorded by wrist-worn IoT device

    study enroll~12 months

  • walking steps and walking time

    mean walking steps and walking time per day, recorded by wrist-worn IoT device

    study enroll~12 months

Secondary Outcomes (3)

  • Pittsburg Sleep Quality Index (PSQI)

    study enroll~12 months

  • Insomnia Severity Index (ISI)

    study enroll~12 months

  • Distress thermometer

    study enroll~12 months

Study Arms (1)

Tamoxifen group

Pre-menopausal breast cancer patients who underwent proper surgical treatment, chemotherapy, or radiation therapy, and are scheduled for application of tamoxifen and goserelin

Drug: Tamoxifen Oral Tablet

Interventions

Patients who are scheduled for application of tamoxifen and goserelin

Tamoxifen group

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Female population, aged 18\~45, diagnosed of unilateral breast cancer (stage 0 \~III), who underwent proper cancer treatment including surgery, chemotherapy, radiation therapy, scheduled for applying tamoxifen and goserelin

You may qualify if:

  • diagnosed of unilateral breast cancer (stage 0 \~III)
  • underwent proper cancer treatment including surgery, chemotherapy, radiation therapy
  • age : 18 \~ 45
  • scheduled for applying tamoxifen and goserelin

You may not qualify if:

  • need CPAP device during sleep due to sleep apnea
  • under medication for restless leg syndrome
  • previous history of tamoxifen
  • irregular bedtime due to shift work
  • diagnosed of recurrent or metastatic cancer
  • have difficulty understanding and conducting surveys and verbal instructions due to severe cognitive, communication and perception problems
  • refuse to participate
  • has musculoskeletal system and neurological damage and lesions

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Samsung Medical Center

Seoul, South Korea

RECRUITING

Related Publications (7)

  • Azim HA Jr, Davidson NE, Ruddy KJ. Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. Am Soc Clin Oncol Educ Book. 2016;35:23-32. doi: 10.1200/EDBK_159069.

    PMID: 27249683BACKGROUND
  • Gonzalez BD, Lu Q. Sleep disturbance among Chinese breast cancer survivors living in the USA. Support Care Cancer. 2018 Jun;26(6):1695-1698. doi: 10.1007/s00520-018-4128-y. Epub 2018 Feb 26.

    PMID: 29484499BACKGROUND
  • Bhave MA, Speth KA, Kidwell KM, Lyden A, Alsamarraie C, Murphy SL, Henry NL. Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer. Clin Breast Cancer. 2018 Apr;18(2):168-174.e2. doi: 10.1016/j.clbc.2017.12.012. Epub 2017 Dec 27.

  • Budhrani PH, Lengacher CA, Kip K, Tofthagen C, Jim H. An integrative review of subjective and objective measures of sleep disturbances in breast cancer survivors. Clin J Oncol Nurs. 2015 Apr;19(2):185-91. doi: 10.1188/15.CJON.185-191.

  • Chen D, Yin Z, Fang B. Measurements and status of sleep quality in patients with cancers. Support Care Cancer. 2018 Feb;26(2):405-414. doi: 10.1007/s00520-017-3927-x. Epub 2017 Oct 23.

  • Yfantis A, Intas G, Tolia M, Nikolaou M, Tsoukalas N, Lymperi M, Kyrgias G, Zografos G, Kontos M. Health-related quality of life of young women with breast cancer. Review of the literature. J BUON. 2018 Jan-Feb;23(1):1-6.

  • Yeo SM, Lim JY, Kim SW, Chae BJ, Yu J, Ryu JM, Hwang JH. Impact of Adjuvant Hormone Therapy on Sleep, Physical Activity, and Quality of Life in Premenopausal Breast Cancer: 12-Month Observational Study. J Breast Cancer. 2023 Apr;26(2):93-104. doi: 10.4048/jbc.2023.26.e11. Epub 2023 Mar 13.

MeSH Terms

Conditions

Sleep Wake DisordersBreast Neoplasms

Interventions

Tamoxifen

Condition Hierarchy (Ancestors)

Nervous System DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsMental DisordersNeoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

StilbenesBenzylidene CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Target Duration
12 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Physical and Rehabilitation Medicine

Study Record Dates

First Submitted

October 3, 2019

First Posted

October 7, 2019

Study Start

August 10, 2018

Primary Completion

December 31, 2020

Study Completion

December 31, 2020

Last Updated

October 7, 2019

Record last verified: 2019-10

Data Sharing

IPD Sharing
Will not share

Locations